Evotec SE has made progress under a strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programs. Evotec receives a $25 million payment to progress further research.

Evotec and Bristol Myers Squibb entered their strategic neuroscience collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases that slow down or reverse disease progression. This progress leverages Evotec’s PanOmics platform in conjunction with patient-derived disease models, which is one of the largest and most sophisticated platforms in the industry.
 
The partnership has generated a promising pipeline of discovery to clinical-stage programs. A first program, EVT8683, was in-licensed by Bristol Myers Squibb in September 2021 as BMS-986419. In March 2023, Bristol Myers Squibb and Evotec extended and expanded their partnership for an additional 8 years.
 
Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, said, “The achieved milestone underlines the productive nature of our neuroscience partnership with Bristol Myers Squibb. Using our PanOmics-driven drug discovery platform we are targeting neurodegenerative diseases with tremendous unmet medical need. Beyond BMS-986419, we are very excited to advance yet another program towards the clinic development in 2026.”